Sitryx advances development of PKM2 modulator SYX-5219 into atopic dermatitis patients following clinical evidence of immunomodulatory activity ...

A research group have discovered a novel modulator for human regulatory T cells. This novel regulator can strengthen or dampen immune response and provides a new basis for therapeutic approaches for ...

Janux Therapeutics, Inc. (Nasdaq: JANX) ("Janux"), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor ...

Neurosterix was spun-out of Addex in April 2024, raising $65 million in a Series A financing led by funds affiliated with Perceptive Advisors. Addex retains a 20% equity interest in Neurosterix.

32 Biosciences, a gastrointestinal (GI)-focused biotechnology company pioneering gut mucosal-immune science to prevent and treat GI diseases, today announced that it will officially launch its $40 ...

New preclinical research in Neuropsychopharmacology focuses on the unique mechanism and site of action of evenamide as a potential treatment for schizophrenia. Subscribe to our newsletter for the ...

As global data traffic soars, transmitting information with light instead of electrical signals is becoming crucial for ...